Talk:Dextromethorphan: Difference between revisions

(2 intermediate revisions by one other user not shown)

Line 56:

On the other hand, [[Wikipedia:Dextromethorphan/bupropion|dextromethorphan/bupropion]] is an approved combination drug; each ''extended-release'' tablet contains 45 mg DXM and 105 mg bupropion. The maximum dose for depression is set at 2 tablets per day, spaced at least 8 hours apart.<ref name="p37859435">McCarthy, B; Bunn, H; Santalucia, M; Wilmouth, C; Muzyk, A; Smith, CM (30 November 2023). "Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder". Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 21 (4): 609–616. doi:10.9758/cpn.23.1081. PMID 37859435. PMC [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10591164/ 10591164]. Retrieved via PMC.</ref> Although this combination drug is safe enough to be approved, the safety of an instant-release combination and of higher doses remains a concern.

</blockquote>

I fixed the error. I don't think [[User:Mnbvcxz]] meant to do that, their description is a minor edit that only fixes bolding and he reversed two different edits in one. [[User:Uzi|Uzi]] ([[User talk:Uzi|talk]]) 03:32, 8 June 2024 (UTC)

So [[User:JH556|JH556]], I ''guess'' the relative safety has something to do with it being extended-release. I don't know how much safety margin goes into the "space doses at least 8hrs apart" disclaimer, but it has to be... decent enough?

Line 72:

Line 74:

==~~Please remove~~ the ~~bolding~~ of the first ~~paragraph~~==

==Plateau Sigma==

I feel like Plateau Sigma shouldn't be called "Fifth Plateau" and should instead be called as its own distinct plateau. By this distinction I think it'll help drive the point that it does not match with the linear dose-effect relationship of the first to fourth plateaus because it involves a certain hepatic phenomenon from redosing that can create a different subjective effect (by dosage tolerability and ↑DXM:↓DXO blood concentration). On a more off-topic note, I think we should talk about warning against redosing DXM too much throughout the day because of this certain effect (e.g. Redosing after CYP2D6 is being pre-occupied by initial dosages). What do you guys think of this? [[User:Uzi|Uzi]] ([[User talk:Uzi|talk]]) 04:07, 8 June 2024 (UTC)

== Legality ==

In reference to "''United States: Dextromethorphan is available over the counter and can be found in grocery stores, convenience stores, and online. Many physical locations requires the purchaser to be over the age of 18, however this is not the law.''"

This should be elaborated on to include the states where the selling of DXM-containing products is restricted to those 18+ in some states such as New York and New Jersey

~~I edited it out~~.

Refs: New York State: https://www.nysenate.gov/legislation/bills/2013/s696/amendment/b, New Jersey: https://legiscan.com/NJ/text/A622/id/926720

@@ Line 56: / Line 56: @@
 On the other hand, [[Wikipedia:Dextromethorphan/bupropion|dextromethorphan/bupropion]] is an approved combination drug; each ''extended-release'' tablet contains 45&nbsp;mg DXM and 105&nbsp;mg bupropion. The maximum dose for depression is set at 2 tablets per day, spaced at least 8 hours apart.<ref name="p37859435">McCarthy, B; Bunn, H; Santalucia, M; Wilmouth, C; Muzyk, A; Smith, CM (30 November 2023). "Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder". Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 21 (4): 609–616. doi:10.9758/cpn.23.1081. PMID 37859435. PMC [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10591164/ 10591164]. Retrieved via PMC.</ref> Although this combination drug is safe enough to be approved, the safety of an instant-release combination and of higher doses remains a concern.
 </blockquote>
+I fixed the error. I don't think [[User:Mnbvcxz]] meant to do that, their description is a minor edit that only fixes bolding and he reversed two different edits in one. [[User:Uzi|Uzi]] ([[User talk:Uzi|talk]]) 03:32, 8 June 2024 (UTC)
 So [[User:JH556|JH556]], I ''guess'' the relative safety has something to do with it being extended-release. I don't know how much safety margin goes into the "space doses at least 8hrs apart" disclaimer, but it has to be... decent enough?
@@ Line 72: / Line 74: @@
 <references />
-==Please remove the bolding of the first paragraph==
+==Plateau Sigma==
+I feel like Plateau Sigma shouldn't be called "Fifth Plateau" and should instead be called as its own distinct plateau. By this distinction I think it'll help drive the point that it does not match with the linear dose-effect relationship of the first to fourth plateaus because it involves a certain hepatic phenomenon from redosing that can create a different subjective effect (by dosage tolerability and ↑DXM:↓DXO blood concentration). On a more off-topic note, I think we should talk about warning against redosing DXM too much throughout the day because of this certain effect (e.g. Redosing after CYP2D6 is being pre-occupied by initial dosages). What do you guys think of this? [[User:Uzi|Uzi]] ([[User talk:Uzi|talk]]) 04:07, 8 June 2024 (UTC)
+== Legality ==
+In reference to "''United States: Dextromethorphan is available over the counter and can be found in grocery stores, convenience stores, and online. Many physical locations requires the purchaser to be over the age of 18, however this is not the law.''"
+This should be elaborated on to include the states where the selling of DXM-containing products is restricted to those 18+ in some states such as New York and New Jersey
-I edited it out.
+Refs: New York State: https://www.nysenate.gov/legislation/bills/2013/s696/amendment/b, New Jersey: https://legiscan.com/NJ/text/A622/id/926720